Sitges-Serra A, Guirao X, Pereira J A, Nubiola P
Department of Surgery, Hospital Universitari de Mar, Universitat Autònoma de Barcelona, Spain.
Digestion. 1993;54 Suppl 1:38-40. doi: 10.1159/000201075.
Pharmacological treatment of patients with enterocutaneous fistulas aims at reducing output, increasing the chance of spontaneous closure and reducing the time of fistula closure. Our initial experience with octreotide suggests that this drug effectively reduces output of established enterocutaneous fistulas when compared with a placebo in patients on parenteral nutrition. Output reduction was independent of the basal output. Likewise, this somatostatin analogue was shown to accelerate fistula closure in a series of 27 patients treated with the drug after having received parenteral nutrition for a mean of 25 days. When compared with a historical series, the rate of spontaneous fistula closure was not modified by octreotide.
肠皮肤瘘患者的药物治疗旨在减少瘘液排出量，增加自然闭合的机会并缩短瘘管闭合时间。我们使用奥曲肽的初步经验表明，与接受肠外营养的患者使用安慰剂相比，这种药物能有效减少已形成的肠皮肤瘘的瘘液排出量。排出量的减少与基础排出量无关。同样，在一系列平均接受了25天肠外营养后使用该药物治疗的27例患者中，这种生长抑素类似物被证明可加速瘘管闭合。与一个历史队列相比，奥曲肽并未改变瘘管自然闭合的发生率。
